These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1466 related items for PubMed ID: 12479764

  • 1. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    JAMA; 2002 Dec 18; 288(23):2998-3007. PubMed ID: 12479764
    [Abstract] [Full Text] [Related]

  • 2. [Clinical study of the month. The ALLHAT-LLT trial].
    Kulbertus H, Scheen AJ.
    Rev Med Liege; 2003 Jan 18; 58(1):53-8. PubMed ID: 12647600
    [Abstract] [Full Text] [Related]

  • 3. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.
    Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, ALLHAT Collaborative Research Group.
    JAMA Intern Med; 2017 Jul 01; 177(7):955-965. PubMed ID: 28531241
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, Simpson LM, Stokes JD, Wiegmann TB, Williamson JD, ALLHAT Collaborative Research Group.
    J Clin Hypertens (Greenwich); 2013 Aug 01; 15(8):542-54. PubMed ID: 23889716
    [Abstract] [Full Text] [Related]

  • 5. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT).
    Margolis KL, Dunn K, Simpson LM, Ford CE, Williamson JD, Gordon DJ, Einhorn PT, Probstfield JL, ALLHAT Collaborative Research Group.
    Am Heart J; 2009 Dec 01; 158(6):948-55. PubMed ID: 19958861
    [Abstract] [Full Text] [Related]

  • 6. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK.
    Circulation; 2017 Nov 14; 136(20):1878-1891. PubMed ID: 28877913
    [Abstract] [Full Text] [Related]

  • 7. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
    Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM.
    Am J Hypertens; 1996 Apr 14; 9(4 Pt 1):342-60. PubMed ID: 8722437
    [Abstract] [Full Text] [Related]

  • 8. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr 19; 283(15):1967-75. PubMed ID: 10789664
    [Abstract] [Full Text] [Related]

  • 9. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G, Tonkin A.
    Ann Intern Med; 2001 May 15; 134(10):931-40. PubMed ID: 11352694
    [Abstract] [Full Text] [Related]

  • 10. ALLHAT-LLT: questions, questions, and more questions (and some answers).
    Skerrett PJ, Pasternak RC.
    Curr Atheroscler Rep; 2004 Sep 15; 6(5):375-80. PubMed ID: 15296704
    [Abstract] [Full Text] [Related]

  • 11. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile JN, Henriquez MA, Huml A, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasinh S, Stanford C, ALLHAT Collaborative Research Group.
    Am J Kidney Dis; 2008 Sep 15; 52(3):412-24. PubMed ID: 18676075
    [Abstract] [Full Text] [Related]

  • 12. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
    Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A, LIPID Study Investigators.
    Circulation; 2002 Mar 12; 105(10):1162-9. PubMed ID: 11889008
    [Abstract] [Full Text] [Related]

  • 13. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    JAMA; 2002 Dec 18; 288(23):2981-97. PubMed ID: 12479763
    [Abstract] [Full Text] [Related]

  • 14. Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.
    Rahman M, Baimbridge C, Davis BR, Barzilay JI, Basile JN, Henriquez MA, Huml A, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasinh S, Stanford C, ALLHAT Collaborative Research Group.
    Clin Nephrol; 2013 Oct 18; 80(4):235-48. PubMed ID: 23816477
    [Abstract] [Full Text] [Related]

  • 15. Effects of pravastatin on exercise electrocardiography test performance and cardiovascular mortality and morbidity in patients with hypercholesterolemia: Lipid Intervention Study in Kyoto.
    Sasaki S, Nakagawa M, Nakata T, Azuma A, Sawada S, Takeda K, Asayama J, Lipid Intrvention Study in Kyoto.
    Circ J; 2002 Jan 18; 66(1):47-52. PubMed ID: 11999665
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A, ALLHAT Collaborative Research Group.
    J Am Coll Cardiol; 2009 Nov 24; 54(22):2023-31. PubMed ID: 19926008
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM.
    JAMA; 1998 May 27; 279(20):1615-22. PubMed ID: 9613910
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.